Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It’s annoying how good I am at making sense isn’t it Prof. Go on, what’s this theory?
Well, well, well so Ripley and Vegas are one in the same.
Prof cheese only the other day you labeled me as a rogue because I'm in the building trade and now your offended because of people being rude after attempting (poor) to trash their investment
I say to you Prof I am more honest and credible than what you'll ever be I'm not the rogue
Fair enough Sleepydave. I certainly don't have a problem with well thought out reasoned responses. After all is said and done a BB is where opinions should be allowed to be expressed and challenged. It's the vitriolic and abusive responses to points of view that others don't agree with that are unnecessary and need to be called out. I don't doubt that Avacta and Medusa are well able to make the test work with the Omicron variant. It is the commerciality of the revised test that I think is in question and this is linked to the seeming ability of the virus to mutate at a rate that, potentially, makes it difficult for a manufacturer to maintain the viability of the test against the likely future incarnations of the virus. Altering the test to provide such longevity will require development time, approval time and not inconsiderable cost. I happen to think that a commercial view might (and I stress the word, might) be taken that the cost/risks of same outweigh the likely return. For all we know such a decision may already have been taken. I can well appreciate that mine might be a minority view on here but I hope you would agree that it one that I am entitled to express.
Hi Profcheese.
Its probably of little consequence whether a particular opinion expressed on here is honest or not.
But the comments in your message of 12:16 are worthy of a response imo.
I agree your first comment about the market.
I don't share your qualms about future variants given that AVCT have already intimated they are (on top of getting the current test back on the rails) conceiving a next generation test with future variants in mind.
Who knows what we shall see.
Will they target S and N as well?
Will they tackle flu too?
Will they defy Burgerman and go back to saliva?
Will we have more than one next gen test?
I don't share your pessimism about the effect on clients of the existing first gen test being "paused"(not withdrawn). Firstly the reason does not relate to the tests previous performance.
Secondly if the test is back on the market before too long what it will suggest to prospective clients imo is how quick footed and efficient (as well as honest) AVACTA are (especially if that is juxtaposed with lack of action on the part of other test makers).
As regards what the Avacta management are "well aware of" look no further than the RNS.
They are slotting in a different antibody into the first gen test as we speak to ensure the previous high performance. Hence as roundhowe points up they can say to future investors that the company benefits from near term revenue generated by affimer diagnostics (and imo they are not just referring to animals)
They are not shy about discussing the long term commercial possibilities of their next gen Covid 19 test.
So maybe your view is honestly expressed and you are just a pessimist.
But imo your vibe is not that projected by AVCT.
In actual fact a re-rate would be my current preference so I can trade my recent top ups and reduce my overall paper losses whilst news of the oncology side develops. Sorry if others interpreted my honest opinion as a deramp.
I do. I just don't need to spend hours, days, weeks, writing super rampy ****e to gain that objective. My money is where my mouth is. x
KENYAN can sell as he owns shares unlike calamari
Calamari, I will propose your new strategy to the city boys. They will go mad for this revolutionary idea
Why not just say you want a lower price to trade this share. Saves all the *******s you write. ;) GLA.
At least give him time to log off and back on as NDN to carry on with the discussion
Dick cheese off on another deramp
It seems that the market is attributing little or no income from LFT sales, at least in the short term. This is reflected in the current SP (IMO). It could be perceived that, even if the test is tweaked to restore reliability for detecting early infectiousness of the Omicron variant, a future VoC might render the test unreliable due to the nature of the part of the virus that the test is targeting. Once a test has been withdrawn from the market, it indicates (to many) potential future unreliability and it will take a lot of convincing manufacturers, distributors and consumers to commit to a revised test. I would imagine that the Avacta management are well aware of this and it would be no surprise (to me) if the LFT is quietly dropped, purely on commercial grounds, especially if the initial AVA6K data is robust. So, for me, this reverts to mainly an oncology play, which is what I originally invested for, rather than a covid play, albeit I believe that some of the current SP is supported by revenues from other partnership possibilities and a potential takeover. The unknown factor is whether Medusa might also take a commercial view and decide to drop the LFT for the same reason. Will it represent "good money after bad" to pursue trying to get the test to the required level that restores confidence in its reliability and gives it the chance of being a commercial success?
The invite to the road show states:
"The company benefits from near-term revenue generated from Affimer diagnostics"
Hopefully more will be revealed this week in the Trading Update.
https://twitter.com/boy_cellar/status/1484809079180693505/photo/1
Exactly.
My optimistic Sunday feeling is hoping for a bullish outlook on the LFT. I.e. more detail/progress on the ABDX partnership. It would be a crying shame if zero revenue is attributed from it. Even a working platform, with the threat of sales will swing the bargaining power closer to Avacta. Without it, licensing premium could be reduced.
Hugely excited for data.
Have you only just realised this? That's why when the derampers drip on about needing funding through a placing it is highly unlikely if AVA6000 initial results are good. Not impossible, because it might be they can't secure a large up front licensing deal, but when P1a is complete in Q2 they will know whether it reduces/gets rids of side effects and if it does, that part of the platform is proven and at that point large pharma will know of the huge commercial opportunity and will likely want to be in on the action. Hence either a licensing deal or early moves for a takeover. If the LFT is not going to get us much (or any) revenue then the P1a data is absolutely pivotal.
https://avactaanimalhealth.com/
It’s mentioned in annual reports I think but is small beans.
Nothing on telly so to speak so I thought i`d look on Avactas web page and in particular on their Investors page and i`ve copied the paragraph and posted below.
Doxorubicin is a $1bn generic drug and a standard of care for many soft tissue sarcomas despite severe cardiotoxicity issues that limits its effectiveness. In the case of Avacta’s improved version of this drug, AVA6000 pro-Doxorubicin that incorporates the pre|CISIONTM tumour targeting technology, a dramatic improvement in safety has been observed in pre-clinical animal models. If a similar reduction in cardiotoxicity is seen in humans in the phase I clinical trial of AVA6000, then there is the potential for a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars. This funding would support all Avacta’s other programmes in future. The pre|CISIONTM technology to improve the safety of a large number of other established chemotherapies and generate similar licensing opportunities. For this reason, the Company is prioritising this programme.
The Group also benefits from revenue generating businesses in the human and veterinary diagnostics market.
2 things that I didn`t realise before.
1, if they can prove AVA6000 is somewhat successful and less toxic, funding and millions of £s will keep the company going.
mouthwatering and with recent news, there a chance we could be looking rosie !
2, where did vetinery applications come into the factor, all seems very logical but no one has mentioned this before.
avacta really seems to be spreading its wings.
next week or two could be very interesting
Kong